Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica

Uniunea Europeană - slovacă - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Uniunea Europeană - slovacă - EMA (European Medicines Agency)

novartis europharm limited  - voretigene neparvovec - leber congenital amaurosis; retinitis pigmentosa - other ophthalmologicals - luxturna je indikovaný na liečbu dospelých a pediatrických pacientov s strate zraku v dôsledku zdedené dystrofia sietnice spôsobené potvrdil biallelic rpe65 mutácie a ktorí majú dostatok životaschopných buniek sietnice.

Uniunea Europeană - slovacă - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - karcinóm, pľúc bez malých buniek - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

abbott medical 3200 lakeside drive 950 54 santa clara, ca spojené štáty americké -

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

zimmer inc. boggs industrial park, 1800 west center street 465 80 warsaw, in spojené štáty americké -

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

smith & nephew inc. 1450 brooks rd. 38116 memphis, tn spojené štáty americké -

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

novo nordisk a/s, dánsko - somatropín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)